{"id":38796,"date":"2026-11-20T14:21:54","date_gmt":"2026-11-20T20:21:54","guid":{"rendered":"https:\/\/brakkeconsulting.com\/?p=38796"},"modified":"2026-11-20T14:22:06","modified_gmt":"2026-11-20T20:22:06","slug":"thoughts-on-third-quarter-earnings","status":"publish","type":"post","link":"https:\/\/brakkeconsulting.com\/pt\/thoughts-on-third-quarter-earnings\/","title":{"rendered":"Considera\u00e7\u00f5es sobre os resultados do terceiro trimestre"},"content":{"rendered":"<div data-olk-copy-source=\"MessageBody\">A temporada de resultados do terceiro trimestre de 2026 est\u00e1 praticamente encerrada. A Zoetis continua a dominar o setor em termos de vendas totais, com vendas acumuladas no 3T26 quase 37% maiores que as da segunda maior empresa. No entanto, os motores de crescimento do setor sofreram mudan\u00e7as significativas. Para as maiores empresas de capital aberto, o crescimento acumulado no 3T, em moeda constante e com a mesma base de escopo, foi o seguinte: IDEXX (+10%), Elanco (+9%), Merck (+5,1%), Virbac (+7,9%), Vetoquinol (+5,4%) e Zoetis (-1%).<\/div>\n<div>\n<p>A principal mudan\u00e7a no desempenho de crescimento pode ser atribu\u00edda \u00e0 inova\u00e7\u00e3o. Tanto a Elanco quanto a Merck investiram no desenvolvimento de novos produtos direcionados a segmentos de mercado dominados pela Zoetis, lan\u00e7ando produtos competitivos nos segmentos de antiparasit\u00e1rios combinados e de longa dura\u00e7\u00e3o, e dermatol\u00f3gicos.<\/p>\n<\/div>\n<div>\n<p>Outro aspecto importante para impulsionar o desempenho \u00e9 o equil\u00edbrio da linha de produtos. A Elanco possui a linha de produtos mais equilibrada, com uma divis\u00e3o em segmentos de 51% para animais de companhia (CA) e 48% para animais de produ\u00e7\u00e3o (L). A divis\u00e3o da Merck \u00e9 de 40\/60 e a da Zoetis, de 67\/32. A maioria das ind\u00fastrias, incluindo a de sa\u00fade animal, opera em ciclos. A diversifica\u00e7\u00e3o \u00e9 fundamental para enfrentar os altos e baixos dos diversos segmentos de mercado.<\/p>\n<\/div>\n<div>\n<p>Em suma, tudo indica que o setor apresentar\u00e1 taxas de crescimento geral em linha com as m\u00e9dias hist\u00f3ricas. Para saber mais sobre o desempenho e as tend\u00eancias do setor, participe da apresenta\u00e7\u00e3o anual sobre o panorama do setor, organizada pela equipe da Brakke, que acontecer\u00e1 na VMX em Orlando e na WVC em Las Vegas no in\u00edcio de 2027.<\/p>\n<\/div>\n<div>Randy Freides<br \/>\n<i>Consultor s\u00eanior<\/i><\/div>","protected":false},"excerpt":{"rendered":"<p>A temporada de resultados do terceiro trimestre de 2026 est\u00e1 praticamente encerrada. A Zoetis continua a dominar o setor em termos de vendas totais, com vendas acumuladas no 3T26 quase 371 trilh\u00f5es de d\u00f3lares maiores que as da segunda maior empresa. No entanto, os motores de crescimento do setor sofreram mudan\u00e7as significativas. Para as maiores empresas de capital aberto, o crescimento acumulado no 3T, em moeda constante e com a mesma base de escopo, foi o seguinte: IDEXX (+101 trilh\u00e3o de d\u00f3lares), Elanco (+91 trilh\u00e3o de d\u00f3lares), Merck (+5,11 trilh\u00e3o de d\u00f3lares), Virbac (+7,91 trilh\u00e3o de d\u00f3lares), Vetoquinol (+5,41 trilh\u00e3o de d\u00f3lares) e Zoetis (-11 trilh\u00e3o de d\u00f3lares). A principal mudan\u00e7a no desempenho do crescimento pode ser atribu\u00edda \u00e0 inova\u00e7\u00e3o. Tanto a Elanco quanto a Merck investiram no desenvolvimento de novos produtos direcionados a segmentos de mercado dominados pela Zoetis, lan\u00e7ando produtos competitivos nos segmentos de antiparasit\u00e1rios combinados e de longa dura\u00e7\u00e3o, e dermatologia. Outro fator que impulsiona o desempenho \u00e9 o equil\u00edbrio da linha de produtos. A Elanco possui a linha de produtos mais equilibrada, com uma divis\u00e3o em segmentos de 51% para animais de companhia (CA) e 48% para animais de produ\u00e7\u00e3o (L). A divis\u00e3o da Merck \u00e9 de 40\/60 e a da Zoetis, de 67\/32. A maioria das ind\u00fastrias, incluindo a sa\u00fade animal, opera em ciclos. A diversifica\u00e7\u00e3o \u00e9 importante para enfrentar os altos e baixos dos v\u00e1rios segmentos de mercado. No final, tudo indica que o setor apresentar\u00e1 taxas de crescimento geral em linha com as m\u00e9dias hist\u00f3ricas. Para saber mais sobre o desempenho e as tend\u00eancias do setor, participe da apresenta\u00e7\u00e3o anual sobre o panorama do setor, organizada pela equipe da Brakke, que acontecer\u00e1 na VMX em Orlando e na WVC em Las Vegas no in\u00edcio de [ano].<\/p>\n<div class=\"view-full-post\"><a href=\"https:\/\/brakkeconsulting.com\/pt\/thoughts-on-third-quarter-earnings\/\" class=\"view-full-post-btn\">Ver postagem completa<\/a><\/div>\n<p>;<\/p>","protected":false},"author":19,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[43],"tags":[],"class_list":["post-38796","post","type-post","status-publish","format-standard","hentry","category-viewpoints"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>News from Brakke Consulting<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/brakkeconsulting.com\/pt\/thoughts-on-third-quarter-earnings\/\" \/>\n<meta property=\"og:locale\" content=\"pt_PT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"News from Brakke Consulting\" \/>\n<meta property=\"og:description\" content=\"Third quarter 2026 earnings season is generally over. Zoetis continues to dominate the industry in terms of overall sales with 3Q26 YTD total sales that are almost 37% larger than the next biggest company. However, industry growth generators have clearly shifted. For the largest public companies, 3Q YTD growth on a constant currency and scope basis was as follows: IDEXX (+10%), Elanco (+9%), Merck (+5.1%), Virbac (+7.9%), Vetoquinol (+5.4%) and Zoetis (-1%). The main shift in growth performance can be attributed to innovation. Both Elanco and Merck have invested in developing new product entrants targeting market segments that Zoetis has dominated, launching competitive products in the combination and long-acting parasiticide, and dermatology segments. Another aspect of bolstering performance is product line balance. Elanco has the most balanced product line with a 51% companion animal (CA) \/48% livestock (L) split into segments. Merck&#8217;s split is 40\/60 and Zoetis is 67\/32. Most industries, including animal health, run in cycles. Diversification is important to weather the ups and downs of the various market segments. In the end, it looks like the industry will deliver overall growth rates in line with historical averages. To learn more about industry performance and trends, please join the Brakke team for the Annual Industry Overview presentation at both VMX in Orlando and WVC in Las Vegas in earlyView Full Post;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/brakkeconsulting.com\/pt\/thoughts-on-third-quarter-earnings\/\" \/>\n<meta property=\"og:site_name\" content=\"Brakke Consulting Website\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-20T20:21:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-20T20:22:06+00:00\" \/>\n<meta name=\"author\" content=\"Amanda McDavid\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Amanda McDavid\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo estimado de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/brakkeconsulting.com\\\/thoughts-on-third-quarter-earnings\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/brakkeconsulting.com\\\/thoughts-on-third-quarter-earnings\\\/\"},\"author\":{\"name\":\"Amanda McDavid\",\"@id\":\"https:\\\/\\\/brakkeconsulting.com\\\/#\\\/schema\\\/person\\\/cbd3330707aa1f20925a2f9d78722615\"},\"headline\":\"Thoughts on Third Quarter Earnings\",\"datePublished\":\"2026-11-20T20:21:54+00:00\",\"dateModified\":\"2026-11-20T20:22:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/brakkeconsulting.com\\\/thoughts-on-third-quarter-earnings\\\/\"},\"wordCount\":219,\"articleSection\":[\"Viewpoints\"],\"inLanguage\":\"pt-PT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/brakkeconsulting.com\\\/thoughts-on-third-quarter-earnings\\\/\",\"url\":\"https:\\\/\\\/brakkeconsulting.com\\\/thoughts-on-third-quarter-earnings\\\/\",\"name\":\"News from Brakke Consulting\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/brakkeconsulting.com\\\/#website\"},\"datePublished\":\"2026-11-20T20:21:54+00:00\",\"dateModified\":\"2026-11-20T20:22:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/brakkeconsulting.com\\\/#\\\/schema\\\/person\\\/cbd3330707aa1f20925a2f9d78722615\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/brakkeconsulting.com\\\/thoughts-on-third-quarter-earnings\\\/#breadcrumb\"},\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/brakkeconsulting.com\\\/thoughts-on-third-quarter-earnings\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/brakkeconsulting.com\\\/thoughts-on-third-quarter-earnings\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/brakkeconsulting.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Thoughts on Third Quarter Earnings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/brakkeconsulting.com\\\/#website\",\"url\":\"https:\\\/\\\/brakkeconsulting.com\\\/\",\"name\":\"Brakke Consulting Website\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/brakkeconsulting.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-PT\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/brakkeconsulting.com\\\/#\\\/schema\\\/person\\\/cbd3330707aa1f20925a2f9d78722615\",\"name\":\"Amanda McDavid\",\"url\":\"https:\\\/\\\/brakkeconsulting.com\\\/pt\\\/author\\\/amanda\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Not\u00edcias da Brakke Consulting","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/brakkeconsulting.com\/pt\/thoughts-on-third-quarter-earnings\/","og_locale":"pt_PT","og_type":"article","og_title":"News from Brakke Consulting","og_description":"Third quarter 2026 earnings season is generally over. Zoetis continues to dominate the industry in terms of overall sales with 3Q26 YTD total sales that are almost 37% larger than the next biggest company. However, industry growth generators have clearly shifted. For the largest public companies, 3Q YTD growth on a constant currency and scope basis was as follows: IDEXX (+10%), Elanco (+9%), Merck (+5.1%), Virbac (+7.9%), Vetoquinol (+5.4%) and Zoetis (-1%). The main shift in growth performance can be attributed to innovation. Both Elanco and Merck have invested in developing new product entrants targeting market segments that Zoetis has dominated, launching competitive products in the combination and long-acting parasiticide, and dermatology segments. Another aspect of bolstering performance is product line balance. Elanco has the most balanced product line with a 51% companion animal (CA) \/48% livestock (L) split into segments. Merck&#8217;s split is 40\/60 and Zoetis is 67\/32. Most industries, including animal health, run in cycles. Diversification is important to weather the ups and downs of the various market segments. In the end, it looks like the industry will deliver overall growth rates in line with historical averages. To learn more about industry performance and trends, please join the Brakke team for the Annual Industry Overview presentation at both VMX in Orlando and WVC in Las Vegas in earlyView Full Post;","og_url":"https:\/\/brakkeconsulting.com\/pt\/thoughts-on-third-quarter-earnings\/","og_site_name":"Brakke Consulting Website","article_published_time":"2026-11-20T20:21:54+00:00","article_modified_time":"2026-11-20T20:22:06+00:00","author":"Amanda McDavid","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Amanda McDavid","Tempo estimado de leitura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/brakkeconsulting.com\/thoughts-on-third-quarter-earnings\/#article","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/thoughts-on-third-quarter-earnings\/"},"author":{"name":"Amanda McDavid","@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615"},"headline":"Thoughts on Third Quarter Earnings","datePublished":"2026-11-20T20:21:54+00:00","dateModified":"2026-11-20T20:22:06+00:00","mainEntityOfPage":{"@id":"https:\/\/brakkeconsulting.com\/thoughts-on-third-quarter-earnings\/"},"wordCount":219,"articleSection":["Viewpoints"],"inLanguage":"pt-PT"},{"@type":"WebPage","@id":"https:\/\/brakkeconsulting.com\/thoughts-on-third-quarter-earnings\/","url":"https:\/\/brakkeconsulting.com\/thoughts-on-third-quarter-earnings\/","name":"Not\u00edcias da Brakke Consulting","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/#website"},"datePublished":"2026-11-20T20:21:54+00:00","dateModified":"2026-11-20T20:22:06+00:00","author":{"@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615"},"breadcrumb":{"@id":"https:\/\/brakkeconsulting.com\/thoughts-on-third-quarter-earnings\/#breadcrumb"},"inLanguage":"pt-PT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/brakkeconsulting.com\/thoughts-on-third-quarter-earnings\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/brakkeconsulting.com\/thoughts-on-third-quarter-earnings\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/brakkeconsulting.com\/"},{"@type":"ListItem","position":2,"name":"Thoughts on Third Quarter Earnings"}]},{"@type":"WebSite","@id":"https:\/\/brakkeconsulting.com\/#website","url":"https:\/\/brakkeconsulting.com\/","name":"Site da Brakke Consulting","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/brakkeconsulting.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-PT"},{"@type":"Person","@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615","name":"Amanda McDavid","url":"https:\/\/brakkeconsulting.com\/pt\/author\/amanda\/"}]}},"_links":{"self":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/38796","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/users\/19"}],"replies":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/comments?post=38796"}],"version-history":[{"count":2,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/38796\/revisions"}],"predecessor-version":[{"id":38798,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/38796\/revisions\/38798"}],"wp:attachment":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/media?parent=38796"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/categories?post=38796"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/tags?post=38796"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}